Title of article
Management of High Disease Activity in Multiple Sclerosis Using ZytuxTM (Rituximab, AryoGen Pharmed): Evidence from a Case Report
Author/Authors
Naser Moghadasi ، Abdorreza Multiple Sclerosis Research Center, Neuroscience Institute - Tehran University of Medical Sciences , Ghoreyshi Tayyebi ، Esmaeil Department of Neurology - Ardabil University of Medical Sciences
From page
1
To page
3
Abstract
Rituximab is an anti-CD20 monoclonal antibody, which is used for the treatment of various autoimmune diseases. Owing to its marked effect on B cells, rituximab has also been used in the treatment of fulminant multiple sclerosis. The present study aimed to describe the case of a patient with fulminant radiological presentation, which was effectively controlled using rituximab. A 21-year-old woman initially presented with vertigo, which resolved spontaneously. The MRI indicated extensive periventricular involvement with multiple enhancing lesions. The patient was hospitalized and received pulse methylprednisolone (1 g) daily for five days. Afterwards, she was administered with ZytuxTM (1 g; rituximab, AryoGen Pharmed) for two weeks.
Keywords
ZytuxTM , Rituximab , Highly Active Multiple Sclerosis , MRI
Journal title
Journal of Kermanshah University of Medical Sciences
Journal title
Journal of Kermanshah University of Medical Sciences
Record number
2508157
Link To Document